KeTang

According to the Zhang Tongshe Link database, there were 16 financing events in Shanghai this week (4.24-4.30), with a total financing amount exceeding 900 million yuan. Excluding undisclosed ones, there are three cases where the financing amount reaches 100 million RMB.

Following Smeglutide, Mounjaro (tirzepatide) from Eli Lilly and Company is expected to be approved for the treatment of obese patients by the end of this year.

On May 4th, Lilly announced that its antibody therapy donanemab for treating Alzheimer's disease had reached the primary endpoint and all secondary endpoints for assessing cognitive and functional decline in phase III clinical trials.

Shaker is a common instrument and equipment, mainly used for bacterial culture, fermentation, hybridization, biochemical reactions, as well as enzyme and cell tissue culture research. Of course, the significance of shaker is also very broad, and it is divided into industrial shaker and biological shaker. Standardized operation and maintenance are also particularly important.

Nowadays, centrifuges are widely used, not only in industries such as mineral processing and coal, but also in cutting-edge industries such as pharmaceuticals and aerospace. Therefore, although the centrifuge is small, its function is very significant. Understanding the working principle and operating methods is also helpful. Below, the editor will give you a detailed introduction, and you must take a closer look.

On August 8, 2021, Rongchang Biotechnology (09995. HK) reached a global exclusive licensing agreement with internationally renowned biopharmaceutical company Seagen Inc. (SGEN) to develop and commercialize its ADC new drug, vidiximab.

Although the Federal Trade Commission (FTC) of the United States has sued to block this transaction, and the European Union is also launching an antitrust investigation, the acquisition case has still been completed.

In addition to safety events, the persistence of gene therapy for hemophilia is also a concern. In August of last year, the FDA rejected the approval of the first Roctavian gene therapy for hemophilia A. The FDA pointed out in the CRL that BioMarin needed more data to support BLA, and recommended that BioMarin complete a phase III clinical study of BMN 270-301 and provide 2-year follow-up data as substantive evidence that the therapy can sustainably maintain annual bleeding rate efficacy. On June 28th of this year, BioMarin once again submitted a Marketing Authorization Application (MAA) to EMA, despite Roctavian's recent disclosure of the gradual decline in efficacy persistence.